Awardee OrganizationLA JOLLA INSTITUTE FOR IMMUNOLOGY
Description
Abstract Text
DESCRIPTION (provided by applicant): The mitochondrial pathway of apoptosis is the major mechanism whereby cells in vertebrate organisms undergo programmed cell death. It is vital for homeostasis of the immune system, tumor suppression and the regulation of cell number in development. Mitochondrial outer membrane permeabilization (MOMP) and release of intermembrane space proteins such as cytochrome C are central to this process. MOMP is controlled by the Bcl-2 family of proteins. Pro-apoptotic members, Bax and Bak, are activated by another subgroup of the Bcl-2 family, BH3-only proteins, and induce the release of intermembrane space proteins. Anti-apoptotic members of the Bcl-2 family inhibit this process. Based on the finding that BH3-only proteins bind to anti-apoptotic Bcl-2 family members to induce apoptosis, drugs that mimic this effect were developed and are being used in cancer therapy. Better understanding of how Bcl-2 family proteins interact with the MOM and induce permeabilization will allow generation of new or even better drugs. The central hypothesis of this proposal is that there are MOM proteins that co- operate with pro-apoptotic Bcl-2 family proteins to generate lipidic pores in the MOM. The object of this application is to identify these molecules and to determine how they contribute to Bax and Bak activation followed by pore formation. Our Specific Aims are: Aim 1. Identify MOM proteins that co-operate with Bid for induction of MOMP. Unknown MOM proteins assist Bid in Bax mediated-permeabilization of membranes. MOM proteins will be fractionated and reconstituted in proteo-liposomes to identify the active fraction by the dextran release assay. We will investigate whether the identified MOM protein knockdown has the same inhibitory effect as Bid deficiency in mouse embryonic fibroblast (MEF) lines. Aim 2. Determine how Bax activation is regulated prior to MOMP. Using a dextran release kinetics assay, we will determine the time course of Bax conformational change and oligomerization in relation to membrane permeabilization. We will also determine the mechanism of Bcl-xL inhibition by analysis of its effect on release kinetics. We will follow up these experiments by examining cytochrome C release kinetics using mitochondria isolated from cytochrome C-GFP expressing cells in time lapse fluorescent microscopy. Aim 3. Demonstrate lipidic pores induced by Bax and Bak and determine whether Bax localizes to these pores. Our cryo-EM data suggest that Bax generates lipidic pores in the membrane. We will use high-pressure freezing/freeze substitution-EM to demonstrate the existence of these pores in OMVs and mitochondria both in isolation and in cells. This technique will allow us to detect pores with immunogold or nanogold labeled Bax. Mapping the distribution of Bax along the edge of the pores will enable us to determine whether Bax pores are mainly lipidic or proteinaceous. PUBLIC HEALTH RELEVANCE: Apoptosis is a fundamental biological process whereby cells execute their own death upon receiving apoptotic signals. Mitochondria, an organelle that sustains life, is also found to play a major role in apoptosis by releasing apoptogenic proteins, which is regulated by a group of proteins in the Bcl-2 family. The proposed study will increase our understanding of molecular mechanisms that underlie mitochondrial outer membrane permeabilization, and enable us to develop more effective therapeutic strategies for diseases such as cancer.
No Sub Projects information available for 7R01GM086389-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7R01GM086389-03
Patents
No Patents information available for 7R01GM086389-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7R01GM086389-03
Clinical Studies
No Clinical Studies information available for 7R01GM086389-03
News and More
Related News Releases
No news release information available for 7R01GM086389-03
History
No Historical information available for 7R01GM086389-03
Similar Projects
No Similar Projects information available for 7R01GM086389-03